i-SENS, Inc.

KOSDAQ 099190.KQ

i-SENS, Inc. EBITDA for the year ending December 31, 2023: USD 17.42 M

i-SENS, Inc. EBITDA is USD 17.42 M for the year ending December 31, 2023, a -30.80% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

i-SENS, Inc. EBITDA for the year ending December 31, 2022 was USD 25.17 M, a -32.76% change year over year.
i-SENS, Inc. EBITDA for the year ending December 31, 2021 was USD 37.43 M, a -1.45% change year over year.
i-SENS, Inc. EBITDA for the year ending December 31, 2020 was USD 37.98 M, a 9.64% change year over year.
i-SENS, Inc. EBITDA for the year ending December 31, 2019 was USD 34.64 M, a 9.98% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

KOSDAQ: 099190.KQ

i-SENS, Inc.

CEO	Dr. Geun-Sig Cha
IPO Date	Jan. 30, 2013
Location	South Korea
Headquarters	43, Banpo-daero 28-gil
Employees	687
Sector	Health Care
Industries Medical Instruments Biotechnology Pharmaceuticals

Description

i-SENS, Inc. provides diagnostic biosensors in South Korea. The company offers point of care testing devices, such as HbA1c, blood gas, electrolyte, and PT/INR analyzers; CareSens blood glucose monitoring systems; and lancing and other ancillary devices, as well as diabetes management services. It exports its products to approximately 110 countries, including the United States, Japan, and Europe. The company was founded in 2000 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years